{"title":"弥漫大 B 细胞淋巴瘤患者骨骼肌质量与治疗反应之间的关系。","authors":"Junice Teresita Sosa-Romero, Lilia Castillo-Martínez, Jesús Alejandro Gabutti-Thomas, Gladys Patricia Agreda-Vásquez","doi":"10.1080/10428194.2024.2386591","DOIUrl":null,"url":null,"abstract":"<p><p>Previous studies have demonstrated that a low skeletal muscle mass (SMM) is an adverse factor for overall survival (OS) in diffuse large B-cell lymphoma (DLBCL). However, its association with the treatment response has not been extensively investigated. This study aimed to determine the association between low skeletal muscle mass (SMM) and treatment response in DLBCL patients. We conducted a retrospective cohort study of 123 patients with DLBCL, in whom SMM was assessed using computed tomography before chemotherapy administration. The demographic characteristics of the patients with low SMM and those with normal SMM were not statistically different. However, there were notable differences in weight and BMI; patients with low SMM had a lower mean weight (59.2 vs 63, <i>p</i> = 0.002) and a higher proportion of patients with normal BMI (61.5% vs. 21.1%, <i>p</i> < 0.001). In addition, patients with low SMM were more likely to receive R-CHOP-like treatment (21.2% vs. 7%, <i>p</i> = 0.022) and experienced more delays in administration (42.9% vs. 33.3%, <i>p</i> = 0.452). Low SMM was not associated with failure to achieve CR (HR 1.9; 95% CI [0.9-4.1] <i>p</i> = 0.84), but it was reported to risk OS in univariate analysis (HR 2.1; 95% CI [1.03-4.2], <i>p</i> = 0.041). An interesting result was the interaction of low SMM with hypertension as a risk factor for not achieving CR (HR 2.7; 95% CI [1.1-6.5] <i>p</i> = 0.034) or OS (HR 7.9; 95% CI [3.4-18.8] <i>p</i> < 0.001). Low SMM was not a risk factor for achieving CR in patients with DLBCL and seemed to play a role in OS.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Association between skeletal muscle mass and treatment response in patients with diffuse large B-cell lymphoma.\",\"authors\":\"Junice Teresita Sosa-Romero, Lilia Castillo-Martínez, Jesús Alejandro Gabutti-Thomas, Gladys Patricia Agreda-Vásquez\",\"doi\":\"10.1080/10428194.2024.2386591\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Previous studies have demonstrated that a low skeletal muscle mass (SMM) is an adverse factor for overall survival (OS) in diffuse large B-cell lymphoma (DLBCL). However, its association with the treatment response has not been extensively investigated. This study aimed to determine the association between low skeletal muscle mass (SMM) and treatment response in DLBCL patients. We conducted a retrospective cohort study of 123 patients with DLBCL, in whom SMM was assessed using computed tomography before chemotherapy administration. The demographic characteristics of the patients with low SMM and those with normal SMM were not statistically different. However, there were notable differences in weight and BMI; patients with low SMM had a lower mean weight (59.2 vs 63, <i>p</i> = 0.002) and a higher proportion of patients with normal BMI (61.5% vs. 21.1%, <i>p</i> < 0.001). In addition, patients with low SMM were more likely to receive R-CHOP-like treatment (21.2% vs. 7%, <i>p</i> = 0.022) and experienced more delays in administration (42.9% vs. 33.3%, <i>p</i> = 0.452). Low SMM was not associated with failure to achieve CR (HR 1.9; 95% CI [0.9-4.1] <i>p</i> = 0.84), but it was reported to risk OS in univariate analysis (HR 2.1; 95% CI [1.03-4.2], <i>p</i> = 0.041). An interesting result was the interaction of low SMM with hypertension as a risk factor for not achieving CR (HR 2.7; 95% CI [1.1-6.5] <i>p</i> = 0.034) or OS (HR 7.9; 95% CI [3.4-18.8] <i>p</i> < 0.001). Low SMM was not a risk factor for achieving CR in patients with DLBCL and seemed to play a role in OS.</p>\",\"PeriodicalId\":18047,\"journal\":{\"name\":\"Leukemia & Lymphoma\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2024-08-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Leukemia & Lymphoma\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/10428194.2024.2386591\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia & Lymphoma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10428194.2024.2386591","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
以往的研究表明,骨骼肌质量(SMM)过低是影响弥漫大B细胞淋巴瘤(DLBCL)患者总生存期(OS)的不利因素。然而,其与治疗反应的关系尚未得到广泛研究。本研究旨在确定低骨骼肌质量(SMM)与弥漫性大B细胞淋巴瘤患者治疗反应之间的关系。我们对123名DLBCL患者进行了回顾性队列研究,在化疗前使用计算机断层扫描评估了他们的骨骼肌质量。低SMM患者和正常SMM患者的人口统计学特征没有统计学差异。然而,体重和体重指数有显著差异;低SMM患者的平均体重较低(59.2 vs. 63,p = 0.002),体重指数正常的患者比例较高(61.5% vs. 21.1%,p = 0.022),且用药延迟时间较长(42.9% vs. 33.3%,p = 0.452)。低 SMM 与未能达到 CR 无关(HR 1.9;95% CI [0.9-4.1],p = 0.84),但据报道,在单变量分析中,低 SMM 会给 OS 带来风险(HR 2.1;95% CI [1.03-4.2],p = 0.041)。一个有趣的结果是,低 SMM 与高血压的交互作用是未达到 CR(HR 2.7;95% CI [1.1-6.5],p = 0.034)或 OS(HR 7.9;95% CI [3.4-18.8],p = 0.034)的风险因素。
Association between skeletal muscle mass and treatment response in patients with diffuse large B-cell lymphoma.
Previous studies have demonstrated that a low skeletal muscle mass (SMM) is an adverse factor for overall survival (OS) in diffuse large B-cell lymphoma (DLBCL). However, its association with the treatment response has not been extensively investigated. This study aimed to determine the association between low skeletal muscle mass (SMM) and treatment response in DLBCL patients. We conducted a retrospective cohort study of 123 patients with DLBCL, in whom SMM was assessed using computed tomography before chemotherapy administration. The demographic characteristics of the patients with low SMM and those with normal SMM were not statistically different. However, there were notable differences in weight and BMI; patients with low SMM had a lower mean weight (59.2 vs 63, p = 0.002) and a higher proportion of patients with normal BMI (61.5% vs. 21.1%, p < 0.001). In addition, patients with low SMM were more likely to receive R-CHOP-like treatment (21.2% vs. 7%, p = 0.022) and experienced more delays in administration (42.9% vs. 33.3%, p = 0.452). Low SMM was not associated with failure to achieve CR (HR 1.9; 95% CI [0.9-4.1] p = 0.84), but it was reported to risk OS in univariate analysis (HR 2.1; 95% CI [1.03-4.2], p = 0.041). An interesting result was the interaction of low SMM with hypertension as a risk factor for not achieving CR (HR 2.7; 95% CI [1.1-6.5] p = 0.034) or OS (HR 7.9; 95% CI [3.4-18.8] p < 0.001). Low SMM was not a risk factor for achieving CR in patients with DLBCL and seemed to play a role in OS.
期刊介绍:
Leukemia & Lymphoma in its fourth decade continues to provide an international forum for publication of high quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies. The scope ranges from clinical and clinico-pathological investigations to fundamental research in disease biology, mechanisms of action of novel agents, development of combination chemotherapy, pharmacology and pharmacogenomics as well as ethics and epidemiology. Submissions of unique clinical observations or confirmatory studies are considered and published as Letters to the Editor